Nureca Ltd (NSE: NURECA, BSE: 543264) is a Chandigarh-based company in the Medical Testing, Analyzing, and Diagnostic Equipment industry. With a market capitalisation of ₹290 Cr, it ranks #2,360 by market cap among the 6,197 Indian listed companies on FinBizNet, and #5 of 7 in Medical Testing, Analyzing, and Diagnostic Equipment. At ₹299.50 (as of 19 Nov 2026), the share price is 20.3% below its 52-week high of ₹376.00 and 46.8% above its 52-week low of ₹204.00. The share price is up 11.3% over one year and down 5.8% over three months.
| Current Price | ₹299.50 |
|---|---|
| Market Cap | ₹290 Cr |
| NSE Symbol | NURECA |
| BSE Code | 543264 |
| Sector | Health Care > Health Care Equipment and Services > Health Care Equipment and Supplies |
| Sub-Industry | Health Care Equipment > Medical Testing, Analyzing, and Diagnostic Equipment |
| P/E Ratio | 143.7 |
| Return on Equity | 1.11% |
| Return on Assets | -0.56% |
| 52-Week Range | ₹204.00 – ₹376.00 |
| 1-Year Price Change | +11.3% |
| 3-Month Price Change | -5.8% |
| Beta (1Y) | 0.88 |
| Dividend Yield | 0.00% |
| Headquarters | Chandigarh |
| Website | www.nureca.com |
| Revenue | ₹59 Cr |
|---|---|
| Net Profit | ₹4 Cr |
| Net Margin | 6.9% |
| EPS (Basic) | ₹4.25 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Nureca Ltd reported revenue of ₹59 Cr in Q2 FY27, up 55.1% from ₹38 Cr in Q2 FY26 and up 45.1% from ₹40 Cr in Q1 FY27. It posted a net profit of ₹4 Cr for the quarter, against a net profit of ₹4 Cr in Q2 FY26 (up 11.6%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹32 Cr (Q4 FY25) to ₹59 Cr (Q2 FY27). The company reported a net loss in 1 of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹59 Cr | ₹4 Cr | 6.9% |
| Q1 FY27 | ₹40 Cr | ₹3 Cr | 7.6% |
| Q4 FY26 | ₹35 Cr | −₹6 Cr | −17.2% |
| Q3 FY26 | ₹40 Cr | ₹4 Cr | 9.4% |
| Q2 FY26 | ₹38 Cr | ₹4 Cr | 9.6% |
| Q1 FY26 | ₹34 Cr | ₹1 Cr | 2.4% |
| Q4 FY25 | ₹32 Cr | ₹2 Cr | 7.8% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 70.68% of Nureca Ltd's shares as of Sept 2026, against 64.97% in Dec 2025 (+5.71 percentage points).
Nureca Limited provides home healthcare and wellness products in India. The company offers chronic disease products, such as nebulizers, blood pressure monitors, finger pulse oximeters, glucose meters, and thermometers, as well as connected products; orthopedic products, including massagers, pain management products, posture correctors, and rehabilitation products; and humidifiers and steamers, personal scales, yoga and exercise products, fitness tracking products, and dental and personal care products. It also provides mother and baby care products comprising baby feeding products, carry cots, baby skincare products, and bottle warmers and steamers; nutritional supplements and weight management products; and ECG products, fitness trackers, and smart weighing scales. In addition, the company provides orthopedic cushions, heating pads, and breast pumps. The company offers its products under the Dr Trust, Dr Physio, and Trumom brands. It markets its products through e-commerce platforms,
1. Home Healthcare and Wellness Products-This segment provides home healthcare and wellness products. It sells its products through e-commerce players, distributors, and retailers.
1. Home Healthcare and Wellness Products-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Molbio Diagnostics Limited | ₹15,196 Cr | 94.7 | — | ₹259 Cr | — |
| Hemant Surgical Industries Lim | ₹939 Cr | 43.4 | — | — | +102.0% |
| Credent Connect N Care | ₹792 Cr | 31 | — | — | — |
| QMS Medical Allied Services Limited | ₹330 Cr | 32.4 | 12.29% | ₹53 Cr | +80.0% |
| Nureca Ltd | ₹290 Cr | 143.7 | 1.11% | ₹59 Cr | +11.3% |
| Earkart Limited | ₹151 Cr | 27.6 | — | ₹0 Cr | -54.3% |
| Avience Biomedicals Limited | ₹144 Cr | 11.7 | 27.86% | — | — |
Listed by market capitalisation. Ratios are shown for context only.
Nureca Ltd is trading at ₹299.50, with a market capitalisation of ₹290 Cr.
Nureca Ltd operates in the Health Care > Health Care Equipment and Services > Health Care Equipment and Supplies space (Health Care Equipment > Medical Testing, Analyzing, and Diagnostic Equipment).
Nureca Ltd has a P/E of 143.7 and a return on equity of 1.11%.
Nureca Ltd is listed on the NSE under the symbol NURECA and on the BSE under the scrip code 543264.
Nureca Ltd's share price is up 11.3% over one year and down 5.8% over three months. Its 52-week range is ₹204.00 to ₹376.00.
In Q2 FY27, Nureca Ltd reported revenue of ₹59 Cr and net profit of ₹4 Cr, with basic EPS of ₹4.25 (consolidated, parsed from the company's exchange filing).
Nureca Ltd reported revenue of ₹59 Cr in Q2 FY27, up 55.1% from ₹38 Cr in Q2 FY26 and up 45.1% from ₹40 Cr in Q1 FY27.
Promoters held 70.68% of Nureca Ltd's shares as of Sept 2026, against 64.97% in Dec 2025 (+5.71 percentage points).
Data as of 19 Nov 2026. Descriptive market data only — not investment advice.